2013-10-15 06:01 AM
MANSFIELD, Mass.--(BUSINESS WIRE)--Oct 14, 2013--Covidien (NYSE: COV), a leading global provider of healthcare products, has released positive final results from its DURABILITY II study and promising preliminary data from its DEFINITIVE AR trial at the Vascular Interventional Advances (VIVA) 2013 conference in Las Vegas, NV. These studies demonstrate the safety and effectiveness of technologies used in the treatment of peripheral arterial disease (PAD). The DURABILITY II three-year results support the use of a single long EverFlex? self-expanding stent. DEFINITIVE AR acute 30-day data shows early success with the combined use of directional atherectomy and a drug-coated balloon (DAART) in treating lower limb blockages in PAD patients.
The DEFINITIVE AR study evaluated the use of directional atherectomy with Covidien's TurboHawk(TM) plaque excision system. (Photo: Business Wire)
"Covidien's extensive clinical research program in vascular therapies aims to provide rigorous evidence that physicians can use to make treatment decisions for conditions, such as peripheral arterial disease ?V a common vascular disease affecting over 200 million people worldwide,"?said Mark Turco, M.D., Chief Medical Officer, Covidien Vascular Therapies.?"Providing clinically relevant data ?V like the DURABILITY II and DEFINITIVE AR trials - to physicians is a must, and I'm proud of Covidien's work to drive this evidence."
In DURABILITY II, the use of the EverFlex? stent demonstrated a low need for repeat procedures (revascularization of treated lesions) as well as a low rate of stent breakage (fracture rate). Stent fracture is a known cause of artery reblockage leading to repeat procedures. Final results support the long-term safety and effectiveness of the EverFlex stent in a challenging PAD patient population.
In the DEFINITIVE AR randomized study, early results show that physicians are achieving better acute procedural success when treating patients with directional atherectomy plus anti-restenotic therapy (DAART) versus using a drug-coated balloon alone. The results also showed superior lumen gain with DAART treatment with fewer vessel tears (dissections) and no "bailout" stents required.
For a summary of research findings, please visit Covidien DURABILITY II and Covidien DEFINITIVE AR.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2012 revenue of $9.9 billion, Covidien has 38,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
Photos/Multimedia Gallery Available:http://www.businesswire.com/multimedia/home/20131014005992/en/
David T. Young, 508-452-1644
Manager, External Communications
Lisa Clemence, 508-452-4375
Coleman Lannum, CFA, 508-452-4343
Todd Carpenter, 508-452-4363
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY CARDIOLOGY CLINICAL TRIALS MEDICAL DEVICES MEDICAL SUPPLIES
Copyright Business Wire 2013
PUB: 10/14/2013 04:15 PM/DISC: 10/14/2013 04:15 PM